← Back to Search

GLP-1 Receptor Agonist

LY3502970 for Type 2 Diabetes

Phase 2

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

Summary

This trial is testing a new medication called LY3502970 to help people with type 2 diabetes control their blood sugar levels. It targets those who haven't had success with diet, exercise, or metformin. The study will last several months to see if LY3502970 is effective and safe.

Eligible Conditions

Type 2 Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose (week (wk) 0, wk 8, wk 12, and wk 26); post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change From Baseline in HbA1c in LY3502970 as Compared to Placebo

Secondary study objectives

Change From Baseline in Body Weight

Change From Baseline in Fasting Serum Glucose

Change From Baseline in HbA1c in LY3502970 as Compared to Dulaglutide

+3 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719

38%

Nausea

21%

Vomiting

16%

Diarrhoea

13%

Constipation

Fatigue

Covid-19

Lipase increased

Dyspepsia

Gastrooesophageal reflux disease

Palpitations

Abdominal distension

Decreased appetite

Eructation

Weight decreased

Arthralgia

Headache

Urticaria

Abdominal pain upper

Upper respiratory tract infection

Muscle spasms

Dizziness

Hypertension

100%

80%

60%

40%

20%

Study treatment Arm

12 mg LY3502970

24 mg LY3502970

36 mg LY3502970 - 1

36 mg LY3502970 - 2

45 mg LY3502970 - 1

Placebo

3 mg LY3502970

45 mg LY3502970 - 2

1.5 mg Dulaglutide

Trial Design

9Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: 45 mg LY3502970 - 2Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Group II: 45 mg LY3502970 - 1Experimental Treatment1 Intervention

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.

Group III: 36 mg LY3502970 - 2Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Group IV: 36 mg LY3502970 - 1Experimental Treatment1 Intervention

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.

Group V: 3 milligrams (mg) LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).

Group VI: 24 mg LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.

Group VII: 12 mg LY3502970Experimental Treatment1 Intervention

Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.

Group VIII: 1.5 mg DulaglutideActive Control1 Intervention

Participants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).

Group IX: PlaceboPlacebo Group1 Intervention

Participants received matching placebo.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3502970

2021